| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/26/2004 | US20040038259 Method of producing a temporally spaced subtracted (TSS) cDNA library and uses thereof |
| 02/26/2004 | US20040038257 Therapeutic peptidase for diagnosis, treatment and prevention of cancer and nervous system disorders |
| 02/26/2004 | US20040038252 Method of testing for allergic diseases |
| 02/26/2004 | US20040038248 Novel polypeptide-human heterogeneous nuclear ribonucleoprotein 32.01 and the polynucleotide encoding said polypeptide |
| 02/26/2004 | US20040038239 A reporter system that transports GPI(glycosyl-phosphatidyl inositol-anchored proteins to the cell wall, was constructed and a gene that inhibit the transportaton of above protein is identified and a antifungal compound is discovered |
| 02/26/2004 | US20040038236 Mutation associated with epilepsy |
| 02/26/2004 | US20040038235 A g-protein coupled receptor |
| 02/26/2004 | US20040038230 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/26/2004 | US20040038223 Comprise polypeptide for diagnosis, prevention and treatment of cardiomyopathy, atherosclerosis, hypertension, cancer, diabetes and nervous system disorders |
| 02/26/2004 | US20040038212 Novel armadillo repeat-containing protein alex1 |
| 02/26/2004 | US20040038210 Comprises nucleotide sequences coding extracellular protein for diagnosis, prevention and treatment of tumors, blood, viral and immunological diseases |
| 02/26/2004 | US20040038209 Comprises nucleotide sequences coding beta -carotene dioxygenase which cleaves beta carotene and produces vitamin a aldehyde; improving nutritional value of plants, microorganisms and animal feeds |
| 02/26/2004 | US20040038203 Comprises nucleotide sequences coding yaba monkey tumor viral protein for treatment and prevention of autoimmune diseases |
| 02/26/2004 | US20040038196 Immunoblobulin directed against smallpox inhibitor of complement enzyme (SPICE) for preventing and treating poxviral infections |
| 02/26/2004 | US20040037893 Aqueous composition also including a buffer to keep the pH in the range of 4.0-8.0, a salt of calcium and/or magnesium in a concentration of >15 mM; stabilised against chemical and/ or physical degradation during storage or transportation |
| 02/26/2004 | US20040037889 Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same |
| 02/26/2004 | US20040037865 Obesity controlling method |
| 02/26/2004 | US20040037853 Botulinum neurotoxin formulated with a recombinant serum albumin |
| 02/26/2004 | US20040037852 Intramuscular or subcutaneous injection to treat a muscle disorder without development of an extensive local hypotonicity |
| 02/26/2004 | US20040037845 Use of flt3-ligand in the treatment of infection |
| 02/26/2004 | US20040037842 Compositions and methods for the therapy and diagnosis of colon cancer |
| 02/26/2004 | US20040037839 T-cell receptor beta-like protein |
| 02/26/2004 | US20040037836 Comprises nitroglycerin; for preventing adverse effects associated with medical device implantation; for inhibiting platelet deposition; angiotensin converting enzyme inhibitors |
| 02/26/2004 | US20040037833 Comprises purified imunoglobulin polypeptide or antigen binding fragment for diagnosis of disease/cancer |
| 02/26/2004 | US20040037832 Transcription factor as repressor of expression of E-cadherin; detecting galactosidase activity; drug screening |
| 02/26/2004 | US20040037831 Pharmaceutical compositon comprising trkaig2 for use inthe prevention and/or treatment of cancer |
| 02/26/2004 | US20040037830 Assaying platelet factor 4 superfamily members (PF4A); interleukins; for medical diagnosis; antiinflammatory agents |
| 02/26/2004 | US20040037829 For immunoregulation and/or treatment of inflammation; muteins |
| 02/26/2004 | US20040037828 Methods and pharmaceutical compositions for healing wounds |
| 02/26/2004 | US20040037826 Combined use of a modulator of CD3 and a GLP-1 compound |
| 02/26/2004 | US20040037825 Tumor cytotoxicity induced by modulators of the CXCR4 receptor |
| 02/26/2004 | US20040037824 Epidermal growth factors (ErbB2); gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037823 Epidermal growth factors (ErbB2); comprises doxorubicin; gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037822 Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system |
| 02/26/2004 | US20040037821 For expression of erythropoietin; genetic translocation; zinc finger motifs |
| 02/26/2004 | US20040037820 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| 02/26/2004 | US20040037819 Non-polymeric hematopoeitic cell clots for delivery of active agents |
| 02/26/2004 | US20040037818 Treatment for diabetes |
| 02/26/2004 | US20040037817 Deleting lympocytes and reactivating thymus via CD34-antigens and/or leutininzing hormone releasing hormone agonists (sex steroids); for alleviation of autoimmune diseases and allergies |
| 02/26/2004 | US20040037816 Graft acceptance through manipulation of thymic regeneration |
| 02/26/2004 | US20040037811 Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
| 02/26/2004 | US20040037809 Intranasal delivery of interferon- beta yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon- beta is delivered to the intranasal mucosa along with one or more intranasal |
| 02/26/2004 | US20040037808 Methods for modulating T cell responses by manipulating a commom cytokine receptor gamma-chain |
| 02/26/2004 | US20040037805 DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of |
| 02/26/2004 | US20040037804 Methods combining glucocorticoids and cytokines for the treatment of inflammatory disorders are disclosed. |
| 02/26/2004 | US20040037803 A G-CSF solution formulation which is substantially free from proteins as a stabilizer but which contains at least one amino acid or a salt thereof as a stabilizer. |
| 02/26/2004 | US20040037802 Activated polymeric bicine derivatives such as polypeptides modified with these polymers exhibit reduced immunogenicity/antigenicity and circulate in the blood |
| 02/26/2004 | US20040037784 Particulate (2S)-3-(4-(((4-(aminocarbonyl)-1-piperidinyl) carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-((2-(2-methylphenoxy) acetyl)amino)pentanoyl)amino) propanoic acid or a salt or solvate thereof and one or more suitable excipients for |
| 02/26/2004 | US20040037781 Peptides with antioxidant and antimicrobial properties |
| 02/26/2004 | US20040037778 Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic |
| 02/26/2004 | US20040037775 Treating and preventing autoimmune diseases. The compositions and methods utilize peptides that are cell-specific. The peptides are conjugated to drugs. The peptide-drug conjugate can be internalized by the targeted cells thereby allowing for |
| 02/26/2004 | DE10309368A1 Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase Pharmaceutical preparation containing RNA as a cofactor of hemostasis |
| 02/26/2004 | DE10225139A1 Verfahren zur Identifizierung von immunreaktiven Peptiden A method for identifying immunoreactive peptides |
| 02/26/2004 | CA2535748A1 Pthrp-derived modulators of smooth muscle proliferation |
| 02/26/2004 | CA2496048A1 Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 02/26/2004 | CA2496005A1 Use of botulinum toxin for the treatment of fine wrinkles and pore size |
| 02/26/2004 | CA2495398A1 Antisense modulation of nav1.3 expression |
| 02/26/2004 | CA2495185A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/26/2004 | CA2495037A1 Antisense modulation of acyl-coa synthetase 1 expression |
| 02/26/2004 | CA2494847A1 Enos mutants useful for gene therapy |
| 02/26/2004 | CA2494845A1 Gene therapy for critical limb ischemia with wild type or mutant enos |
| 02/26/2004 | CA2494293A1 Treatment of liver deseases |
| 02/26/2004 | CA2494147A1 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/26/2004 | CA2494132A1 Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes |
| 02/26/2004 | CA2493928A1 Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer |
| 02/26/2004 | CA2493925A1 Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer |
| 02/26/2004 | CA2493923A1 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer |
| 02/26/2004 | CA2493921A1 Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer |
| 02/25/2004 | EP1391516A1 Von willebrand factor (vwf)-cleaving enzyme |
| 02/25/2004 | EP1391514A1 Pharmaceutical composition for treatment of angiogenesis-dependent conditions |
| 02/25/2004 | EP1391513A1 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| 02/25/2004 | EP1391512A1 Polypeptide serving as angiogenic marker and dna thereof |
| 02/25/2004 | EP1391477A1 Method for preparing free flow resin |
| 02/25/2004 | EP1391461A1 Bicyclic lactam inhibitors of interleukin-1-beta converting enzyme |
| 02/25/2004 | EP1391221A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 02/25/2004 | EP1391214A1 Gene transfer of angiogenic factor for skin disease |
| 02/25/2004 | EP1391207A1 Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids |
| 02/25/2004 | EP1391206A1 Pharmaceutical compositions comprising arsenic for the treatment of lymphoma |
| 02/25/2004 | EP1391205A1 Pharmaceutical composition with RNA as cofactor of hemostasis |
| 02/25/2004 | EP1390547A1 Antisense modulation of interleukin 12 p35 subunit expression |
| 02/25/2004 | EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 02/25/2004 | EP1390536A1 Antisense modulation of tumor necrosis factor receptor 2 expression |
| 02/25/2004 | EP1390521A1 Glycopeptide antibiotics |
| 02/25/2004 | EP1390518A2 Buffer solution for electroporation and a method comprising the use of the same |
| 02/25/2004 | EP1390508A2 A retinoic acid metabolizing cytochrome p450 |
| 02/25/2004 | EP1390505A2 Antigens of group b streptococcus and corresponding dna fragments |
| 02/25/2004 | EP1390502A2 Interferon-alpha induced gene |
| 02/25/2004 | EP1390497A2 Human cdnas and proteins and uses thereof |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390493A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 02/25/2004 | EP1390490A2 Muscle-specific expression vectors |
| 02/25/2004 | EP1390487A1 Expression of membrane proteins using an adenylyl cyclase of mycobacterium tuberculosis |
| 02/25/2004 | EP1390486A2 Isolated human aminoacylase, nucleic acid molecules encoding human aminoacylase, and uses thereof |
| 02/25/2004 | EP1390483A2 Gene encoding molecular motor protein and diagnosis method for the disease related to the gene |
| 02/25/2004 | EP1390479A2 P450 proteins |
| 02/25/2004 | EP1390478A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody |
| 02/25/2004 | EP1390472A2 Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
| 02/25/2004 | EP1390468A2 Identification of essential genes of aspegillus fumigatus and methods of use |
| 02/25/2004 | EP1390410A1 Molecules for disease detection and treatment |
| 02/25/2004 | EP1390408A1 A molecular marker |